Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in Smith-Magenis Syndrome (SMS)
Phase of Trial: Phase II/III
Latest Information Update: 10 Dec 2018
Price : $35 *
At a glance
- Drugs Tasimelteon (Primary)
- Indications Circadian rhythm sleep disorders
- Focus Proof of concept; Therapeutic Use
- Sponsors Vanda Pharmaceuticals
- 10 Dec 2018 Primary endpoint (daily diary sleep quality (DDSQ) (50% worst sleep quality)) has been met, according to a Vanda Pharmaceuticals media release.
- 10 Dec 2018 Results presented in the Vanda Pharmaceuticals media release.
- 14 Feb 2018 According to a Vanda Pharmaceuticals media release, results from this trial are expected by the end of 2018.